194 related articles for article (PubMed ID: 25295731)
1. Acylation of Glucagon-like peptide-2: interaction with lipid membranes and in vitro intestinal permeability.
Trier S; Linderoth L; Bjerregaard S; Andresen TL; Rahbek UL
PLoS One; 2014; 9(10):e109939. PubMed ID: 25295731
[TBL] [Abstract][Full Text] [Related]
2. Acylation of salmon calcitonin modulates in vitro intestinal peptide flux through membrane permeability enhancement.
Trier S; Linderoth L; Bjerregaard S; Strauss HM; Rahbek UL; Andresen TL
Eur J Pharm Biopharm; 2015 Oct; 96():329-37. PubMed ID: 26347924
[TBL] [Abstract][Full Text] [Related]
3. Enteroendocrine-derived glucagon-like peptide-2 controls intestinal amino acid transport.
Lee J; Koehler J; Yusta B; Bahrami J; Matthews D; Rafii M; Pencharz PB; Drucker DJ
Mol Metab; 2017 Mar; 6(3):245-255. PubMed ID: 28271031
[TBL] [Abstract][Full Text] [Related]
4. [Improvement of intestinal absorption of peptide and protein drugs by chemical modification with fatty acids].
Yamamoto A
Nihon Rinsho; 1998 Mar; 56(3):601-7. PubMed ID: 9549343
[TBL] [Abstract][Full Text] [Related]
5. Permeability characteristics of tetragastrins across intestinal membranes using the Caco-2 monolayer system: comparison between acylation and application of protease inhibitors.
Fujita T; Kawahara I; Quan Y; Hattori K; Takenaka K; Muranishi S; Yamamoto A
Pharm Res; 1998 Sep; 15(9):1387-92. PubMed ID: 9755890
[TBL] [Abstract][Full Text] [Related]
6. Impact of amino acid replacements on in vitro permeation enhancement and cytotoxicity of the intestinal absorption promoter, melittin.
Maher S; Devocelle M; Ryan S; McClean S; Brayden DJ
Int J Pharm; 2010 Mar; 387(1-2):154-60. PubMed ID: 20025949
[TBL] [Abstract][Full Text] [Related]
7. Self-Assembly of Exendin-4-Derived Dual Peptide Agonists is Mediated by Acylation and Correlated to the Length of Conjugated Fatty Acyl Chains.
Wolff M; Schüler A; Gast K; Seckler R; Evers A; Pfeiffer-Marek S; Kurz M; Nagel N; Haack T; Wagner M; Thalhammer A
Mol Pharm; 2020 Mar; 17(3):965-978. PubMed ID: 31968941
[TBL] [Abstract][Full Text] [Related]
8. Enhancing Oral Bioavailability of Cyclic RGD Hexa-peptides by the Lipophilic Prodrug Charge Masking Approach: Redirection of Peptide Intestinal Permeability from a Paracellular to Transcellular Pathway.
Schumacher-Klinger A; Fanous J; Merzbach S; Weinmüller M; Reichart F; Räder AFB; Gitlin-Domagalska A; Gilon C; Kessler H; Hoffman A
Mol Pharm; 2018 Aug; 15(8):3468-3477. PubMed ID: 29976060
[TBL] [Abstract][Full Text] [Related]
9. Interactions of oral permeation enhancers with lipid membranes in simulated intestinal environments.
Larsen NW; Kostrikov S; Hansen MB; Hjørringgaard CU; Larsen NB; Andresen TL; Kristensen K
Int J Pharm; 2024 Apr; 654():123957. PubMed ID: 38430950
[TBL] [Abstract][Full Text] [Related]
10. Enteral nutrients potentiate the intestinotrophic action of glucagon-like peptide-2 in association with increased insulin-like growth factor-I responses in rats.
Liu X; Murali SG; Holst JJ; Ney DM
Am J Physiol Regul Integr Comp Physiol; 2008 Dec; 295(6):R1794-802. PubMed ID: 18832087
[TBL] [Abstract][Full Text] [Related]
11. GLP-2 Acutely Prevents Endotoxin-Related Increased Intestinal Paracellular Permeability in Rats.
Maruta K; Takajo T; Akiba Y; Said H; Irie E; Kato I; Kuwahara A; Kaunitz JD
Dig Dis Sci; 2020 Sep; 65(9):2605-2618. PubMed ID: 32006214
[TBL] [Abstract][Full Text] [Related]
12. A head-to-head Caco-2 assay comparison of the mechanisms of action of the intestinal permeation enhancers: SNAC and sodium caprate (C
Twarog C; Liu K; O'Brien PJ; Dawson KA; Fattal E; Illel B; Brayden DJ
Eur J Pharm Biopharm; 2020 Jul; 152():95-107. PubMed ID: 32387703
[TBL] [Abstract][Full Text] [Related]
13. Intestinotrophic glucagon-like peptide-2 (GLP-2) activates intestinal gene expression and growth factor-dependent pathways independent of the vasoactive intestinal peptide gene in mice.
Yusta B; Holland D; Waschek JA; Drucker DJ
Endocrinology; 2012 Jun; 153(6):2623-32. PubMed ID: 22535770
[TBL] [Abstract][Full Text] [Related]
14. Bioactive self-assembling lipid-like peptides as permeation enhancers for oral drug delivery.
Karavasili C; Spanakis M; Papagiannopoulou D; Vizirianakis IS; Fatouros DG; Koutsopoulos S
J Pharm Sci; 2015 Jul; 104(7):2304-11. PubMed ID: 25994901
[TBL] [Abstract][Full Text] [Related]
15. Influence of acylation on the adsorption of GLP-2 to hydrophobic surfaces.
Pinholt C; Kapp SJ; Bukrinsky JT; Hostrup S; Frokjaer S; Norde W; Jorgensen L
Int J Pharm; 2013 Jan; 440(1):63-71. PubMed ID: 22310460
[TBL] [Abstract][Full Text] [Related]
16. Polyunsaturated fatty acids reduce non-receptor-mediated transcellular permeation of protein across a model of intestinal epithelium in vitro.
Rosella O; Sinclair A; Gibson PR
J Gastroenterol Hepatol; 2000 Jun; 15(6):626-31. PubMed ID: 10921416
[TBL] [Abstract][Full Text] [Related]
17.
Frimann TM; Ko SK; Harris P; Bukrinski JT; Peters GHJ
J Biomol Struct Dyn; 2023 Jul; 41(11):5007-5021. PubMed ID: 35612899
[TBL] [Abstract][Full Text] [Related]
18. Glucagon-like peptide 2 (GLP-2), an intestinotrophic mediator.
Thulesen J
Curr Protein Pept Sci; 2004 Feb; 5(1):51-65. PubMed ID: 14965320
[TBL] [Abstract][Full Text] [Related]
19. Mechanistic analysis for drug permeation through intestinal membrane.
Hayashi M; Tomita M
Drug Metab Pharmacokinet; 2007 Apr; 22(2):67-77. PubMed ID: 17495413
[TBL] [Abstract][Full Text] [Related]
20. Prototypic G protein-coupled receptor for the intestinotrophic factor glucagon-like peptide 2.
Munroe DG; Gupta AK; Kooshesh F; Vyas TB; Rizkalla G; Wang H; Demchyshyn L; Yang ZJ; Kamboj RK; Chen H; McCallum K; Sumner-Smith M; Drucker DJ; Crivici A
Proc Natl Acad Sci U S A; 1999 Feb; 96(4):1569-73. PubMed ID: 9990065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
